FDA approved Wegovy HD (semaglutide 7.2 mg), a higher-dose once-weekly injectable, after the STEP UP trial showed an average 20.7% weight loss. The approval expands Novo Nordisk's Wegovy franchise and should be material to the company’s obesity drug revenue and competitive positioning.
FDA approved Wegovy HD (semaglutide 7.2 mg), a higher-dose once-weekly injectable, after the STEP UP trial showed an average 20.7% weight loss. The approval expands Novo Nordisk's Wegovy franchise and should be material to the company’s obesity drug revenue and competitive positioning.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
extremely positive
Sentiment Score
0.90
Ticker Sentiment
